Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Net Income towards Common Stockholders of -$47.6 million for Q1 2026, down 11.89% sequentially from -$42.5 million in Q4 2025, and up 22.4% YoY from -$38.9 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$47.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 22.4% year-over-year to -$47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$209.4 million (up 18.85% YoY) and the FY2025 annual result came in at -$223.1 million, up 13.77% from the prior year.
- Net Income towards Common Stockholders retreated to -$47.6 million in Q1 2026 per RCKT's latest filing, from -$42.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$42.5 million in Q4 2025 and troughed at -$69.6 million in Q2 2024.
- A 5-year average of -$58.6 million and a median of -$60.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders sank 57.57% in 2022, then grew 29.49% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$66.7 million in 2022, then grew by 10.59% to -$59.7 million in 2023, then declined by 1.12% to -$60.3 million in 2024, then advanced by 29.49% to -$42.5 million in 2025, then fell by 11.89% to -$47.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$47.6 million, -$42.5 million, and -$50.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 123.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.21 Mn |
| Mar 31, 2026 | -47.59 Mn |
| Dec 31, 2025 | -42.54 Mn |
| Sep 30, 2025 | -50.33 Mn |
| Jun 30, 2025 | -68.92 Mn |
| Mar 31, 2025 | -61.33 Mn |
| Dec 31, 2024 | -60.33 Mn |
| Sep 30, 2024 | -66.72 Mn |
| Jun 30, 2024 | -69.65 Mn |
| Mar 31, 2024 | -62.05 Mn |
| Dec 31, 2023 | -59.66 Mn |
| Sep 30, 2023 | -61.90 Mn |
| Jun 30, 2023 | -65.70 Mn |
| Mar 31, 2023 | -58.34 Mn |
| Dec 31, 2022 | -66.72 Mn |
| Sep 30, 2022 | -57.76 Mn |
| Jun 30, 2022 | -54.40 Mn |
| Mar 31, 2022 | -42.98 Mn |
| Dec 31, 2021 | -44.25 Mn |
| Sep 30, 2021 | -50.12 Mn |